Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120

Benzinga Newsdesk www.benzinga.com Neutral 74.3%

Neg 0% Neu 74.3% Pos 0%

Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.